Select a medication above to begin.
GamaSTAN S/ D
immune globulin (human)
Black Box Warnings .
Thrombosis
may occur with immune globulin products; risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, venous or arterial thrombosis history, estrogen use, indwelling central vascular catheter, hyperviscosity, and cardiovascular disease risk; thrombosis may occur in patients without risk factors; ensure adequate hydration before administration; monitor for signs/symptoms of thrombosis and assess blood viscosity in patients with hyperviscosity risk
Adult Dosing .
Dosage forms: INJ
hepatitis A prophylaxis
- [pre-exposure, travel duration <1mo]
- Dose: 0.1 mL/kg/dose IM x1; Info: may give with hepatitis A vaccine if patients >40 yo, immunocompromised, chronic liver disease, close contacts, occupational risk; see CDC Pre-Travel Vaccine recommendations in Guidelines > Specialties > Infectious Diseases
- [pre-exposure, travel duration >1mo]
- Dose: 0.2 mL/kg/dose IM x1; Info: may give with hepatitis A vaccine if patients >40 yo, immunocompromised, chronic liver disease, close contacts, occupational risk; repeat dose q2mo if continued exposure or until vaccinated; see CDC Pre-Travel Vaccine recommendations in Guidelines > Specialties > Infectious Diseases
- [post-exposure]
- Dose: 0.1 mL/kg/dose IM x1 within 14 days of exposure; Info: may give with hepatitis A vaccine in patients >40 yo; give with hepatitis A vaccine if immunocompromised, chronic liver disease, close contacts, occupational risk
measles prophylaxis
- [0.25 mL/kg/dose IM x1 within 6 days of exposure]
varicella prophylaxis
- [0.6-1.2 mL/kg/dose IM x1]
- Start: ASAP after exposure; Info: give if varicella zoster immune globulin unavailable
rubella prophylaxis
- [0.55 mL/kg/dose IM x1]
- Info: for pregnant patients who will not consider pregnancy termination
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ
hepatitis A prophylaxis (off-label)
- [pre-exposure, travel duration <1mo]
- Dose: 0.1 mL/kg/dose IM x1; Info: may give with hepatitis A vaccine in patients 12 mo and older if immunocompromised, chronic liver disease, close contacts, occupational risk; see CDC Pre-Travel Vaccine recommendations in Guidelines > Specialties > Infectious Diseases
- [pre-exposure, travel duration >1mo]
- Dose: 0.2 mL/kg/dose IM x1; Info: repeat dose q2mo if continued exposure or until vaccinated; may give with hepatitis A vaccine in patients 12 mo and older if immunocompromised, chronic liver disease, close contacts, occupational risk; see CDC Pre-Travel Vaccine recommendations in Guidelines > Specialties > Infectious Diseases
- [post-exposure]
- Dose: 0.1 mL/kg/dose IM x1 within 14 days of exposure; Info: give with hepatitis A vaccine in patients 12 mo and older if immunocompromised, chronic liver disease, close contacts, occupational risk
measles prophylaxis (off-label)
- [immunocompetent patients]
- Dose: 0.25 mL/kg/dose IM x1 within 6 days of exposure; Max: 15 mL/dose
- [immunocompromised patients]
- Dose: 0.5 mL/kg/dose IM x1 within 6 days of exposure; Max: 15 mL/dose
varicella prophylaxis (off-label)
- [0.6-1.2 mL/kg/dose IM x1]
- Start: ASAP after exposure; Info: give if varicella zoster immune globulin unavailable
rubella prophylaxis (off-label)
- [0.55 mL/kg/dose IM x1]
- Info: for pregnant patients who will not consider pregnancy termination
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]